The ambition of SDCC encompasses these three objectives:
- Become one of the best treatment options globally for people with diabetes in a coherent health care system
- Become one of the world's leading clinical diabetes research environments
- That the Capital Region and Greater Copenhagen become a global beacon in innovative diabetes education.
SDCC has been established following a $ 2.95 billion donation from the Novo Nordisk Foundation, which, in addition to the many joint activities in the region, also makes it possible to build entirely new physical settings in the form of a new diabetes center where up to 14,000 people with diabetes can be treated. This center will be completed by 2020 and will be erected next to Herlev Hospital.
Until the new center is completed, treatment will continue on Niels Steensens Vej in Gentofte.